Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Brokerages

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has been assigned an average rating of “Buy” from the nineteen brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $71.8824.

A number of research analysts have weighed in on the company. Morgan Stanley set a $97.00 price target on Xenon Pharmaceuticals in a research note on Monday, March 9th. Stifel Nicolaus set a $66.00 price objective on Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Wedbush cut their price objective on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a report on Monday, March 16th. Guggenheim reissued a “buy” rating and issued a $90.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Friday, January 9th.

Insider Activity

In related news, CEO Ian Mortimer sold 270,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $60.33, for a total value of $16,289,100.00. Following the completion of the sale, the chief executive officer directly owned 6,000 shares in the company, valued at approximately $361,980. This trade represents a 97.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Andrea Difabio sold 2,607 shares of Xenon Pharmaceuticals stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total value of $156,706.77. Following the transaction, the insider owned 4,893 shares of the company’s stock, valued at $294,118.23. The trade was a 34.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 336,707 shares of company stock valued at $19,622,565 in the last quarter. Company insiders own 4.07% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of XENE. Holocene Advisors LP acquired a new stake in shares of Xenon Pharmaceuticals in the second quarter valued at approximately $56,637,000. Wellington Management Group LLP increased its holdings in shares of Xenon Pharmaceuticals by 66.0% during the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after acquiring an additional 1,435,096 shares during the last quarter. Geode Capital Management LLC raised its stake in Xenon Pharmaceuticals by 1,294.2% in the 2nd quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company’s stock valued at $30,369,000 after acquiring an additional 900,746 shares during the period. Braidwell LP raised its stake in Xenon Pharmaceuticals by 33.0% in the 2nd quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock valued at $112,837,000 after acquiring an additional 895,154 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Xenon Pharmaceuticals by 1,968.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock valued at $38,650,000 after purchasing an additional 820,608 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $54.42 on Tuesday. The stock has a market capitalization of $4.53 billion, a price-to-earnings ratio of -12.48 and a beta of 0.91. The business has a 50-day moving average of $45.31 and a 200-day moving average of $42.64. Xenon Pharmaceuticals has a fifty-two week low of $26.74 and a fifty-two week high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter last year, the business earned ($0.84) earnings per share. On average, sell-side analysts expect that Xenon Pharmaceuticals will post -3.1 EPS for the current year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.